Bristol Myers Squibb News

NEW YORK &#8212 Shares of some top pharmaceuticals companies are up at 10 a.m.: Baxter International Inc.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Bristol-Myers Squibb Company Announces Successful Completion of Cash Tender Offer for Shares of Inhibitex, Inc.

In this article, I will examine recent bullish and bearish calls made by Jim Cramer on CNBC's Mad Money TV program.

Since I first promoted Gilead Sciences in my bullish article here , the stock has taken off like a rocket and gained 40.8%, beating the Dow Jones more than 6x over.

Seattle Genetics, Inc. A will unveil its latest earnings on Monday, February 13, 2012.A The average estimate of analysts is for a loss of 30 cents per share, a narrower loss from the year earlier quarter net loss of 34 cents.

Forest Laboratories, Inc. and partner Gedeon Richter recently presented positive top-line results on their antipsychotic candidate, cariprazine .

Bristol-Myers Squibb Company : Jim Cramer ranked this stock a Buy . The stock closed at $32.08, its 52-week high is $35.44, and its 52-week low is $24.97. Buffalo Wild Wings Inc.

Just three months before the world's second-best-selling drug gets U.S. generic competition, a generics company has paid nearly $445 million to finally end a decade-long, twist-filled patent infringement battle with two heavyweight drugmakers over blood thinner Plavix.

Revenues for the fourth quarter ended December 31, 2011 were $93.3 million, compared to $40.8 million for the comparable period in 2010.

Pharmaceutical companies remain under pressure as they deal with increased competition from each other, which threatens their market share.

Goldman Sachs , Morgan Stanley : "Goldman Sachs is going higher. Nobody likes the stock...I also think Morgan Stanley is a buy, buy, buy." Pfizer , Bristol Myers : "Don't sell ...it's got that big buyback...is it my favorite? No, I like others more...but PFE is protected by that yield.

You may remember that in my February column last year I predicted that 2011 would "frustrate bulls and bears alike-without a big directional trend" and "end up or down just by a hair." I was right, but my stock picking could have been better.

NEW YORK -- Here's what Jim Cramer had to say about some of the stocks that callers offered up during the "Mad Money Lightning Round" Wednesday evening.

James Barrow is executive director of Dallas-based investment firm Barrow, Hanley, Mewhinney & Strauss, the lead portfolio manager for the Vanguard Windsor II and Selected Value Funds.

Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.

A major generic drugmaker has paid Bristol-Myers Squibb Co. and Sanofi SA more than $442 million to end a decade-long patent infringement case over blockbuster blood thinner Plavix, the world's second-best-selling drug.

Late Monday, Greece announced plans to lay off 15,000 public-sector workers by year's end according to The Wall Street Journal.

BMY ) lowered their earnings estimates for fiscal 2012. The pharma major reported lower-than-expected earnings and revenues in the final quarter of 2011.

NEW YORK &#8212 Shares of some top pharmaceuticals companies are mixed at 1 p.m.: Baxter International Inc.

Shares of PROLOR Biotech, Inc. have been on the move since we told readers about the company in January and jumped another 5.2% this past week.